![]() |
||||||
|
![]() | Fusion Gene Summary |
![]() | Fusion Gene ORF analysis |
![]() | Fusion Genomic Features |
![]() | Fusion Protein Features |
![]() | Fusion Gene Sequence |
![]() | Fusion Gene PPI analysis |
![]() | Related Drugs |
![]() | Related Diseases |
Fusion gene:CLCN6-BRAF (FusionGDB2 ID:HG1185TG673) |
Fusion Gene Summary for CLCN6-BRAF |
![]() |
Fusion gene information | Fusion gene name: CLCN6-BRAF | Fusion gene ID: hg1185tg673 | Hgene | Tgene | Gene symbol | CLCN6 | BRAF | Gene ID | 1185 | 673 |
Gene name | chloride voltage-gated channel 6 | B-Raf proto-oncogene, serine/threonine kinase | |
Synonyms | CLC-6 | B-RAF1|B-raf|BRAF1|NS7|RAFB1 | |
Cytomap | ('CLCN6')('BRAF') 1p36.22 | 7q34 | |
Type of gene | protein-coding | protein-coding | |
Description | chloride transport protein 6chloride channel, voltage-sensitive 6 | serine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene | |
Modification date | 20200313 | 20200329 | |
UniProtAcc | P51797 | P15056 | |
Ensembl transtripts involved in fusion gene | ENST00000376492, ENST00000312413, ENST00000346436, ENST00000376487, ENST00000376496, ENST00000376497, | ||
Fusion gene scores | * DoF score | 3 X 2 X 3=18 | 48 X 58 X 16=44544 |
# samples | 3 | 69 | |
** MAII score | log2(3/18*10)=0.736965594166206 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(69/44544*10)=-6.0124909441832 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: CLCN6 [Title/Abstract] AND BRAF [Title/Abstract] AND fusion [Title/Abstract] | ||
Most frequent breakpoint | |||
Anticipated loss of major functional domain due to fusion event. |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
![]() |
Partner | Gene | GO ID | GO term | PubMed ID |
Tgene | BRAF | GO:0000186 | activation of MAPKK activity | 29433126 |
Tgene | BRAF | GO:0006468 | protein phosphorylation | 17563371 |
Tgene | BRAF | GO:0010828 | positive regulation of glucose transmembrane transport | 23010278 |
Tgene | BRAF | GO:0033138 | positive regulation of peptidyl-serine phosphorylation | 19667065 |
Tgene | BRAF | GO:0043066 | negative regulation of apoptotic process | 19667065 |
Tgene | BRAF | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 22065586 |
Tgene | BRAF | GO:0071277 | cellular response to calcium ion | 18567582 |
Tgene | BRAF | GO:0090150 | establishment of protein localization to membrane | 23010278 |
![]() * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
ChimerKB3 | . | . | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
Top |
Fusion Gene ORF analysis for CLCN6-BRAF |
![]() * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
3UTR-3CDS | ENST00000376492 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
In-frame | ENST00000312413 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
In-frame | ENST00000346436 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
In-frame | ENST00000376487 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
In-frame | ENST00000376496 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
In-frame | ENST00000376497 | ENST00000288602 | CLCN6 | chr1 | 11867247 | + | BRAF | chr7 | 140481493 | - |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
ENST00000312413 | CLCN6 | chr1 | 11867247 | + | ENST00000288602 | BRAF | chr7 | 140481493 | - | 1365 | 260 | 113 | 1246 | 377 |
ENST00000346436 | CLCN6 | chr1 | 11867247 | + | ENST00000288602 | BRAF | chr7 | 140481493 | - | 1304 | 199 | 52 | 1185 | 377 |
ENST00000376497 | CLCN6 | chr1 | 11867247 | + | ENST00000288602 | BRAF | chr7 | 140481493 | - | 1302 | 197 | 50 | 1183 | 377 |
ENST00000376487 | CLCN6 | chr1 | 11867247 | + | ENST00000288602 | BRAF | chr7 | 140481493 | - | 1274 | 169 | 22 | 1155 | 377 |
ENST00000376496 | CLCN6 | chr1 | 11867247 | + | ENST00000288602 | BRAF | chr7 | 140481493 | - | 1255 | 150 | 3 | 1136 | 377 |
![]() |
Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CLCN6-BRAF |
![]() |
Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
Top |
Fusion Protein Features for CLCN6-BRAF |
![]() Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:/chr7:) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
![]() |
![]() |
Hgene | Tgene |
CLCN6 | BRAF |
FUNCTION: Voltage-gated channel mediating the exchange of chloride ions against protons. Functions as antiporter and contributes to the acidification of the late endosome lumen. The CLC channel family contains both chloride channels and proton-coupled anion transporters that exchange chloride or another anion for protons. The presence of conserved gating glutamate residues is typical for family members that function as antiporters. {ECO:0000269|PubMed:20466723}. | FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}. |
![]() * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CLCN6-BRAF |
![]() |
>17005_17005_1_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000312413_BRAF_chr7_140481493_ENST00000288602_length(transcript)=1365nt_BP=260nt AGTCCCAGAGCTCGAGAGGGCCACGTGACCGTCCCGGGGCCAGTCACGTGAGGCGCAGATCCTGGCTGGGAGGGGGTTGGTAGAGGGGTC CAGAGTGGCAGTAAAGGAGGAAGATGGCGGGGTGCAGGGGGTCTCTGTGCTGCTGCTGCAGGTGGTGCTGCTGCTGCGGTGAGCGTGAGA CCCGCACCCCCGAGGAGCTGACCATCCTTGGAGAAACACAGGAGGAGGAGGATGAGATTCTTCCAAGGAAAGACTATGAGAAAACACTTG GTAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTGGAACAGTCT ACAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCAAAAATGAAG TAGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTACCCAGTGGT GTGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGACAGACTGCAC AGGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCACAGTAAAAA TAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGCAC CAGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAATTGATGACTG GACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCAGTAAGGTAC GGAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCCAAATTCTCG CCTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGG ATTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACAAATGAGTGA GAGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAATTGAATAAAATACTCTCTTTTTTTTTA >17005_17005_1_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000312413_BRAF_chr7_140481493_ENST00000288602_length(amino acids)=377AA_BP=49 MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYEKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGD VAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHA KSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNI NNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACA -------------------------------------------------------------- >17005_17005_2_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000346436_BRAF_chr7_140481493_ENST00000288602_length(transcript)=1304nt_BP=199nt CTGGCTGGGAGGGGGTTGGTAGAGGGGTCCAGAGTGGCAGTAAAGGAGGAAGATGGCGGGGTGCAGGGGGTCTCTGTGCTGCTGCTGCAG GTGGTGCTGCTGCTGCGGTGAGCGTGAGACCCGCACCCCCGAGGAGCTGACCATCCTTGGAGAAACACAGGAGGAGGAGGATGAGATTCT TCCAAGGAAAGACTATGAGAAAACACTTGGTAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAG AATTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACC TCAGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAA GCCACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAA ACTTATAGATATTGCACGACAGACTGCACAGGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATAT ATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACA GTTGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATT TGGAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGG ATACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGA TGAGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTC CTTGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGC GTTTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTA >17005_17005_2_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000346436_BRAF_chr7_140481493_ENST00000288602_length(amino acids)=377AA_BP=49 MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYEKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGD VAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHA KSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNI NNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACA -------------------------------------------------------------- >17005_17005_3_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376487_BRAF_chr7_140481493_ENST00000288602_length(transcript)=1274nt_BP=169nt AGAGTGGCAGTAAAGGAGGAAGATGGCGGGGTGCAGGGGGTCTCTGTGCTGCTGCTGCAGGTGGTGCTGCTGCTGCGGTGAGCGTGAGAC CCGCACCCCCGAGGAGCTGACCATCCTTGGAGAAACACAGGAGGAGGAGGATGAGATTCTTCCAAGGAAAGACTATGAGAAAACACTTGG TAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTGGAACAGTCTA CAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCAAAAATGAAGT AGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTACCCAGTGGTG TGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGACAGACTGCACA GGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCACAGTAAAAAT AGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGCACC AGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAATTGATGACTGG ACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCAGTAAGGTACG GAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCCAAATTCTCGC CTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGGA TTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACAAATGAGTGAG AGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAATTGAATAAAATACTCTCTTTTTTTTTAA >17005_17005_3_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376487_BRAF_chr7_140481493_ENST00000288602_length(amino acids)=377AA_BP=49 MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYEKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGD VAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHA KSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNI NNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACA -------------------------------------------------------------- >17005_17005_4_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376496_BRAF_chr7_140481493_ENST00000288602_length(transcript)=1255nt_BP=150nt AAGATGGCGGGGTGCAGGGGGTCTCTGTGCTGCTGCTGCAGGTGGTGCTGCTGCTGCGGTGAGCGTGAGACCCGCACCCCCGAGGAGCTG ACCATCCTTGGAGAAACACAGGAGGAGGAGGATGAGATTCTTCCAAGGAAAGACTATGAGAAAACACTTGGTAGACGGGACTCGAGTGAT GATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAATTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGTGGCATGGT GATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTCAGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCAGGAAAACA CGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGCCACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCAGCTTGTAT CACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAACTTATAGATATTGCACGACAGACTGCACAGGGCATGGATTACTTACAC GCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATATTTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCT ACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGTTGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCAGAATGCAA GATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTGGAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTTATTCAAAC ATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGATACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTCCAAAAGCC ATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATGAGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGCTGCTGGCC CGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCTTGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTATATGCTTGT GCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGTTTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGAGAGTAGCA >17005_17005_4_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376496_BRAF_chr7_140481493_ENST00000288602_length(amino acids)=377AA_BP=49 MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYEKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGD VAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHA KSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNI NNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACA -------------------------------------------------------------- >17005_17005_5_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376497_BRAF_chr7_140481493_ENST00000288602_length(transcript)=1302nt_BP=197nt GGCTGGGAGGGGGTTGGTAGAGGGGTCCAGAGTGGCAGTAAAGGAGGAAGATGGCGGGGTGCAGGGGGTCTCTGTGCTGCTGCTGCAGGT GGTGCTGCTGCTGCGGTGAGCGTGAGACCCGCACCCCCGAGGAGCTGACCATCCTTGGAGAAACACAGGAGGAGGAGGATGAGATTCTTC CAAGGAAAGACTATGAGAAAACACTTGGTAGACGGGACTCGAGTGATGATTGGGAGATTCCTGATGGGCAGATTACAGTGGGACAAAGAA TTGGATCTGGATCATTTGGAACAGTCTACAAGGGAAAGTGGCATGGTGATGTGGCAGTGAAAATGTTGAATGTGACAGCACCTACACCTC AGCAGTTACAAGCCTTCAAAAATGAAGTAGGAGTACTCAGGAAAACACGACATGTGAATATCCTACTCTTCATGGGCTATTCCACAAAGC CACAACTGGCTATTGTTACCCAGTGGTGTGAGGGCTCCAGCTTGTATCACCATCTCCATATCATTGAGACCAAATTTGAGATGATCAAAC TTATAGATATTGCACGACAGACTGCACAGGGCATGGATTACTTACACGCCAAGTCAATCATCCACAGAGACCTCAAGAGTAATAATATAT TTCTTCATGAAGACCTCACAGTAAAAATAGGTGATTTTGGTCTAGCTACAGTGAAATCTCGATGGAGTGGGTCCCATCAGTTTGAACAGT TGTCTGGATCCATTTTGTGGATGGCACCAGAAGTCATCAGAATGCAAGATAAAAATCCATACAGCTTTCAGTCAGATGTATATGCATTTG GAATTGTTCTGTATGAATTGATGACTGGACAGTTACCTTATTCAAACATCAACAACAGGGACCAGATAATTTTTATGGTGGGACGAGGAT ACCTGTCTCCAGATCTCAGTAAGGTACGGAGTAACTGTCCAAAAGCCATGAAGAGATTAATGGCAGAGTGCCTCAAAAAGAAAAGAGATG AGAGACCACTCTTTCCCCAAATTCTCGCCTCTATTGAGCTGCTGGCCCGCTCATTGCCAAAAATTCACCGCAGTGCATCAGAACCCTCCT TGAATCGGGCTGGTTTCCAAACAGAGGATTTTAGTCTATATGCTTGTGCTTCTCCAAAAACACCCATCCAGGCAGGGGGATATGGTGCGT TTCCTGTCCACTGAAACAAATGAGTGAGAGAGTTCAGGAGAGTAGCAACAAAAGGAAAATAAATGAACATATGTTTGCTTATATGTTAAA >17005_17005_5_CLCN6-BRAF_CLCN6_chr1_11867247_ENST00000376497_BRAF_chr7_140481493_ENST00000288602_length(amino acids)=377AA_BP=49 MAGCRGSLCCCCRWCCCCGERETRTPEELTILGETQEEEDEILPRKDYEKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGD VAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHA KSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNI NNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACA -------------------------------------------------------------- |
Top |
Fusion Gene PPI Analysis for CLCN6-BRAF |
![]() |
![]() |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
![]() |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CLCN6-BRAF |
![]() (DrugBank Version 5.1.8 2021-05-08) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08881 | Vemurafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB08896 | Regorafenib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB14840 | Ripretinib | Inhibitor | Small molecule | Approved |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB00398 | Sorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB08912 | Dabrafenib | Antagonist|Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB11718 | Encorafenib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Tgene | BRAF | P15056 | DB12010 | Fostamatinib | Inhibitor | Small molecule | Approved|Investigational |
Top |
Related Diseases for CLCN6-BRAF |
![]() (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | C0025202 | melanoma | 24 | CGI;CTD_human;UNIPROT | |
Tgene | C1275081 | Cardio-facio-cutaneous syndrome | 14 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT | |
Tgene | C0009402 | Colorectal Carcinoma | 8 | CTD_human;UNIPROT | |
Tgene | C0028326 | Noonan Syndrome | 8 | CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET | |
Tgene | C0238463 | Papillary thyroid carcinoma | 8 | CTD_human;ORPHANET | |
Tgene | C0040136 | Thyroid Neoplasm | 6 | CGI;CTD_human | |
Tgene | C0151468 | Thyroid Gland Follicular Adenoma | 6 | CTD_human | |
Tgene | C0175704 | LEOPARD Syndrome | 6 | CLINGEN;GENOMICS_ENGLAND | |
Tgene | C0549473 | Thyroid carcinoma | 6 | CGI;CTD_human | |
Tgene | C3150970 | NOONAN SYNDROME 7 | 5 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C0009404 | Colorectal Neoplasms | 4 | CTD_human | |
Tgene | C3150971 | LEOPARD SYNDROME 3 | 4 | CTD_human;GENOMICS_ENGLAND;UNIPROT | |
Tgene | C1519086 | Pilomyxoid astrocytoma | 3 | ORPHANET | |
Tgene | C0004565 | Melanoma, B16 | 2 | CTD_human | |
Tgene | C0009075 | Melanoma, Cloudman S91 | 2 | CTD_human | |
Tgene | C0018598 | Melanoma, Harding-Passey | 2 | CTD_human | |
Tgene | C0023443 | Hairy Cell Leukemia | 2 | CGI;ORPHANET | |
Tgene | C0025205 | Melanoma, Experimental | 2 | CTD_human | |
Tgene | C0033578 | Prostatic Neoplasms | 2 | CTD_human | |
Tgene | C0152013 | Adenocarcinoma of lung (disorder) | 2 | CGI;CTD_human | |
Tgene | C0376358 | Malignant neoplasm of prostate | 2 | CTD_human | |
Tgene | C0587248 | Costello syndrome (disorder) | 2 | CLINGEN;CTD_human | |
Tgene | C3501843 | Nonmedullary Thyroid Carcinoma | 2 | CTD_human | |
Tgene | C3501844 | Familial Nonmedullary Thyroid Cancer | 2 | CTD_human | |
Tgene | C0002448 | Ameloblastoma | 1 | CTD_human | |
Tgene | C0004114 | Astrocytoma | 1 | CTD_human | |
Tgene | C0010276 | Craniopharyngioma | 1 | CTD_human;ORPHANET | |
Tgene | C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | CTD_human | |
Tgene | C0017638 | Glioma | 1 | CGI;CTD_human | |
Tgene | C0019621 | Histiocytosis, Langerhans-Cell | 1 | CGI;ORPHANET | |
Tgene | C0022665 | Kidney Neoplasm | 1 | CTD_human | |
Tgene | C0023903 | Liver neoplasms | 1 | CTD_human | |
Tgene | C0024232 | Lymphatic Metastasis | 1 | CTD_human | |
Tgene | C0024694 | Mandibular Neoplasms | 1 | CTD_human | |
Tgene | C0027659 | Neoplasms, Experimental | 1 | CTD_human | |
Tgene | C0027962 | Melanocytic nevus | 1 | GENOMICS_ENGLAND | |
Tgene | C0036920 | Sezary Syndrome | 1 | CTD_human | |
Tgene | C0041409 | Turner Syndrome, Male | 1 | CTD_human | |
Tgene | C0079773 | Lymphoma, T-Cell, Cutaneous | 1 | CTD_human | |
Tgene | C0205768 | Subependymal Giant Cell Astrocytoma | 1 | CTD_human | |
Tgene | C0206686 | Adrenocortical carcinoma | 1 | CTD_human | |
Tgene | C0206754 | Neuroendocrine Tumors | 1 | CTD_human | |
Tgene | C0259783 | mixed gliomas | 1 | CTD_human | |
Tgene | C0278875 | Adult Craniopharyngioma | 1 | CTD_human | |
Tgene | C0280783 | Juvenile Pilocytic Astrocytoma | 1 | CTD_human | |
Tgene | C0280785 | Diffuse Astrocytoma | 1 | CTD_human | |
Tgene | C0334579 | Anaplastic astrocytoma | 1 | CGI;CTD_human | |
Tgene | C0334580 | Protoplasmic astrocytoma | 1 | CTD_human | |
Tgene | C0334581 | Gemistocytic astrocytoma | 1 | CTD_human | |
Tgene | C0334582 | Fibrillary Astrocytoma | 1 | CTD_human | |
Tgene | C0334583 | Pilocytic Astrocytoma | 1 | CGI;CTD_human | |
Tgene | C0338070 | Childhood Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0345904 | Malignant neoplasm of liver | 1 | CTD_human | |
Tgene | C0376407 | Granulomatous Slack Skin | 1 | CTD_human | |
Tgene | C0406803 | Syringocystadenoma Papilliferum | 1 | GENOMICS_ENGLAND | |
Tgene | C0431128 | Papillary craniopharyngioma | 1 | CTD_human | |
Tgene | C0431129 | Adamantinous Craniopharyngioma | 1 | CTD_human | |
Tgene | C0547065 | Mixed oligoastrocytoma | 1 | CTD_human | |
Tgene | C0555198 | Malignant Glioma | 1 | CTD_human | |
Tgene | C0596263 | Carcinogenesis | 1 | CTD_human | |
Tgene | C0684249 | Carcinoma of lung | 1 | CGI;UNIPROT | |
Tgene | C0740457 | Malignant neoplasm of kidney | 1 | CTD_human | |
Tgene | C0750935 | Cerebral Astrocytoma | 1 | CTD_human | |
Tgene | C0750936 | Intracranial Astrocytoma | 1 | CTD_human | |
Tgene | C0751061 | Craniopharyngioma, Child | 1 | CTD_human | |
Tgene | C0920269 | Microsatellite Instability | 1 | CTD_human | |
Tgene | C1527404 | Female Pseudo-Turner Syndrome | 1 | CTD_human | |
Tgene | C1704230 | Grade I Astrocytoma | 1 | CTD_human | |
Tgene | C1721098 | Replication Error Phenotype | 1 | CTD_human | |
Tgene | C2239176 | Liver carcinoma | 1 | CTD_human | |
Tgene | C4551484 | Leopard Syndrome 1 | 1 | GENOMICS_ENGLAND | |
Tgene | C4551602 | Noonan Syndrome 1 | 1 | CTD_human | |
Tgene | C4721532 | Lymphoma, Non-Hodgkin, Familial | 1 | UNIPROT | |
Tgene | C4733333 | familial non-medullary thyroid cancer | 1 | GENOMICS_ENGLAND |